Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.
Saillard M, Cenerenti M, Reichenbach P, Guillaume P, Su Z, Hafezi M, Schmidt J, Cesbron J, Genolet R, Queiroz L, Racle J, Villard J, Renella R, Michielin O, Zoete V, Rivals JP, Irving M, Speiser DE, Harari A, Gfeller D, Adotevi O, Ceppi F, Coukos G, Romero P, Jandus C.
Saillard M, et al. Among authors: su z.
Sci Adv. 2025 Jun 27;11(26):eadu5754. doi: 10.1126/sciadv.adu5754. Epub 2025 Jun 27.
Sci Adv. 2025.
PMID: 40577481
Free PMC article.